These remain good days for Swiss drug and diagnostics giant Roche (Nasdaq:RHHBY), as the company continues to see double-digit growth across most of its oncology franchise, with ongoing growth in diagnostics and early signs of additional operating leverage. While Roche's oncology pipeline looks solid, it's well worth asking if management has been too slow to move to bulk up other areas. Although Roche shares still look a little undervalued, M&A speculation is likely to remain in play for the foreseeable future, likely adding volatility to the shares.
Good Leverage Leads To Upside In The First Half
Although Roche's top-line results were almost exactly in line with expectations, the company still managed to beat operating assumptions by a meaningful amount due to more effective marketing leverage.
Revenue rose 5% (in constant currency) this quarter, led by 6% growth in the pharma business and 3% growth in the diagnostics business. Within drugs, Avastin and the company's HER2 franchise continue to grow at double-digit rates, while Lucentis was also up by double digits. Within diagnostics, Roche's professional business was up 6% (similar to Abbott (NYSE:ABT)), with double-digit growth in immunoassay. Tissue diagnostics was also pretty good (up 6%), while molecular diagnostics was weak and up only 1%. Roche's negative 5% performance in diabetes was poor, but at least better than Johnson & Johnson (NYSE:JNJ) as the major testing companies suffer through a harsher reimbursement environment.
SEE: Evaluating Pharmaceutical Companies

On the margin side, Roche was already a fairly strong performer. Nevertheless, marketing expense growth of just 3% allowed the company to post 10% growth in operating income (or 7% netting out pension adjustments), with pharma up 8% and diagnostics up 9%. On a margin basis, Roche outperformed the average sell-side target by 120bp.
Forget Alexion, But M&A Makes Sense
As I expected, Roche threw cold water on the notion of buying Alexion (Nasdaq: ALXN), the orphan drug specialist. While Alexion looked like a very expensive deal for Roche, and one with high execution risk and minimal synergies, the notion that Roche should and will do deals is sound.
Over 60% of the company's pharmaceutical sales come from oncology, and Roche has seen some embarrassing trial failures in areas like diabetes and cardiovascular disease in its attempts to diversify. Although there are some interesting and high-potential drugs in the pipeline (including a Glyt-1 inhibitor for schizophrenia, etrolizumab in ulcerative colitis, and crenezeumab in Alzheimer's disease), Roche would likely do well for itself by adding more heft to its non-oncology operations.

The question, though, is one of price. With the multi-year bull market in biotech having spiked valuations, there aren't many bargains left. Still, I could see Roche possibly having some interest in companies like Biogen Idec (Nasdaq: BIIB), Vertex (Nasdaq: VRTX), or other orphan drug companies were valuations to ease off over the next year or two.
An Attractive Pipeline Moving Forward
Roche still has an attractive pipeline of its own. Between Roche management and comments from Bristol-Myers (NYSE: BMY), it sounds as though the timeline for PDL-1 could be shorter, and GA101 looks well-positioned as a follow-on to Rituxan (a drug where biosimilar competition in Europe is starting to look like more of a threat).

SEE: The Value Investor's Handbook
The Bottom Line
Even with the strong performance in these shares over the past year, there still seems to be some value left. With long-term free cash flow growth in the neighborhood of 5%, a fair value in the mid-to-high $60s is reasonable. While Pfizer (NYSE: PFE) may have more upside with respect to current growth expectations, Roche remains one of the more attractive large-cap pharmaceuticals, with relatively limited patent risk and several significant pipeline/launch developments over the next 12 months.
Disclosure – As of this writing, the author owns shares of Roche.

Related Articles
  1. Stock Analysis

    The Biggest Risks of Investing in Pfizer Stock

    Learn the biggest potential risks that may affect the price of Pfizer's stock, complete with a fundamental analysis and review of other external factors.
  2. Stock Analysis

    Allstate: How Being Boring Earns it Billions (ALL)

    A summary of what Allstate Insurance sells and whom it sells it to including recent mergers and acquisitions that have helped boost its bottom line.
  3. Options & Futures

    Cyclical Versus Non-Cyclical Stocks

    Investing during an economic downturn simply means changing your focus. Discover the benefits of defensive stocks.
  4. Investing Basics

    How to Deduct Your Stock Losses

    Held onto a stock for too long? Selling at a loss is never ideal, but it is possible to minimize the damage. Here's how.
  5. Economics

    Is Wall Street Living in Denial?

    Will remaining calm and staying long present significant risks to your investment health?
  6. Stock Analysis

    When Will Dick's Sporting Goods Bounce Back? (DKS)

    Is DKS a bargain here?
  7. Investing News

    How AT&T Evolved into a Mobile Phone Giant

    A third of Americans use an AT&T mobile phone. How did it evolve from a state-sponsored monopoly, though antitrust and a technological revolution?
  8. Stock Analysis

    Home Depot: Can its Shares Continue Climbing?

    Home Depot has outperformed the market by a wide margin in the last 12 months. Is this sustainable?
  9. Stock Analysis

    Yelp: Can it Regain its Losses in 2016? (YELP)

    Yelp investors have had reason to be happy recently. Will the good spirits last?
  10. Stock Analysis

    Is Walmart's Rally Sustainable? (WMT)

    Walmart is enjoying a short-term rally. Is it sustainable? Is Amazon still a better bet?
  1. How do dividends affect retained earnings?

    When a company issues a cash dividend to its shareholders, the retained earnings listed on the balance sheet are reduced ... Read Full Answer >>
  2. What is the difference between called-up share capital and paid-up share capital?

    The difference between called-up share capital and paid-up share capital is investors have already paid in full for paid-up ... Read Full Answer >>
  3. Why would a corporation issue convertible bonds?

    A convertible bond represents a hybrid security that has bond and equity features; this type of bond allows the conversion ... Read Full Answer >>
  4. How does additional paid in capital affect retained earnings?

    Both additional paid-in capital and retained earnings are entries under the shareholders' equity section of a company's balance ... Read Full Answer >>
  5. What types of capital are not considered share capital?

    The money a business uses to fund operations or growth is called capital, and there are a number of capital sources available. ... Read Full Answer >>
  6. What is the difference between issued share capital and subscribed share capital?

    The difference between subscribed share capital and issued share capital is the former relates to the amount of stock for ... Read Full Answer >>

You May Also Like

Trading Center